Sun Pharma receives USFDA nod for anti-cancer injection
New Delhi: Sun Pharmaceutical Industries today said it has received US health regulator`s approval to market generic version of Doxil injection, used in treating ovarian cancer in the American market.
The Mumbai-headquartered firm, in a statement, said its subsidiary has received approval from US food and Drug Administration (USFDA) for its Doxorubicin HCl Liposome Injection.
"This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC," the company said.
Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 per cent from their previous close.